Company Directory

Clinical Services International (CSI) is a global leader in the sourcing and management of quality certified commercially available medicines – comparators, concomitant drugs and rescue medication – for clinical trials.

Clinical Start Up Solutions is a company specialising in Study Start Up for Clinical Trials within the UK and Ireland. We specialise in all aspects of Study Start Up Activities – including but not limited to HRA approvals and NHS contract negotiations.

Clinigen (Clinigen Group) is a global pharmaceutical and services company with a unique combination of businesses focused on providing access to medicines to improve the quality of people's lives around the world.

Clinion provides EDC, RTSM, CTMS, eCOA and Document Automation Solutions in an Integrated, cloud-based eClinical platform. Clinion’s eClinical platform is one of the industry’s most fully integrated clinical trial software.

Clinion is a life sciences technology company offering innovative software solutions in the pharmaceutical industry since 2010.

Not only are we committed to conducting regulatory and clinical development programs to the highest levels of quality and efficiency, but we strive to improve the way clinical research is performed and to advance the future of health care with our personal approach and cutting-edge technology.

Clinitude is the first Clinical Research Organisation to offer CRA Liaisons, providing cost-effective site monitoring for the medical device, biotechnology, and pharmaceutical industry. We are innovative, dynamic and your cost is our expertise. We are privately-owned Clinical Research Organisation with more than 12 years of experience effectively managing clinical trials

Clintec (an IQVIA company), established for 22 years, is an award-winning, full-service global clinical research organisation. Our head quarter office is based in Scotland, UK and we have operations across 50+ countries worldwide.

Coave Therapeutics is a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central Nervous System) and eye diseases. Coave Therapeutics’ next-generation AAV-Ligand Conjugate (‘ALIGATER’) platform enables targeted delivery and enhanced gene transduction to improve the effectiveness of advanced gene therapies for rare diseases. The company is advancing a pipeline of novel therapies targeting CNS and eye diseases where targeted gene therapy using chemically modified AAVs (coAAVs) has the potential to be most effective. Coave Therapeutics, which is headquartered in Paris (France), is backed by leading international life science and strategic investors Seroba Life Sciences, Théa Open Innovation, eureKARE, Fund+, Omnes Capital, V-Bio Ventures, Kurma Partners, Idinvest, GO Capital and Sham Innovation Santé/Turenne.